Global and United States Dipeptidyl Peptidase-4 Inhibitors Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and United States Dipeptidyl Peptidase-4 Inhibitors Market Report & Forecast 2024-2034
A dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) is a type of medication used to treat type 2 diabetes. DPP-4 is an enzyme that breaks down the hormone incretin, which stimulates insulin release from pancreatic beta cells. By inhibiting DPP-4, DPP-4 inhibitors increase incretin levels and improve glucose control in patients with type 2 diabetes. Examples of DPP-4 inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin. These drugs are taken orally, usually once daily, and are generally well tolerated. They can be used alone or in combination with other diabetes medications, such as metformin or insulin.
Market Analysis and InsightsGlobal and United States Dipeptidyl Peptidase-4 Inhibitors Market
This report focuses on global and United States Dipeptidyl Peptidase-4 Inhibitors market, also covers the segmentation data of other regions in regional level and county level.
The global Dipeptidyl Peptidase-4 Inhibitors revenue was US$ 12800 million in 2024 and is forecast to a readjusted size of US$ 18820 million by 2034 with a CAGR of 5.4% during the forecast period (2024-2034).
In United States the Dipeptidyl Peptidase-4 Inhibitors revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Dipeptidyl Peptidase-4 Inhibitors include Merck, Boehringer Ingelheim, AstraZeneca, Takeda Pharmaceutical, Novartis, Jiangsu Hansoh Pharmaceutical, Qilu Pharmaceutical, Beijing Tide Pharmaceutical and CTTQ, etc. The global five biggest players hold a share of % in 2024.
Global Dipeptidyl Peptidase-4 Inhibitors Scope and Market Size
Dipeptidyl Peptidase-4 Inhibitors market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Dipeptidyl Peptidase-4 Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the Dipeptidyl Peptidase-4 Inhibitors market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.
Merck
Boehringer Ingelheim
AstraZeneca
Takeda Pharmaceutical
Novartis
Jiangsu Hansoh Pharmaceutical
Qilu Pharmaceutical
Beijing Tide Pharmaceutical
CTTQ
Jiangsu Deyuan Pharmaceutical
Jiujiang Zhongtian Pharmaceutical
Yabao Pharmaceutical
Segment by Type
Sitagliptin
Saxagliptin
Vildagliptin
Linagliptin
Alogliptin
Other
Hospital
Clinic
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Dipeptidyl Peptidase-4 Inhibitors definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Dipeptidyl Peptidase-4 Inhibitors companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Dipeptidyl Peptidase-4 Inhibitors in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Dipeptidyl Peptidase-4 Inhibitors sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Market Analysis and InsightsGlobal and United States Dipeptidyl Peptidase-4 Inhibitors Market
This report focuses on global and United States Dipeptidyl Peptidase-4 Inhibitors market, also covers the segmentation data of other regions in regional level and county level.
The global Dipeptidyl Peptidase-4 Inhibitors revenue was US$ 12800 million in 2024 and is forecast to a readjusted size of US$ 18820 million by 2034 with a CAGR of 5.4% during the forecast period (2024-2034).
In United States the Dipeptidyl Peptidase-4 Inhibitors revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Dipeptidyl Peptidase-4 Inhibitors include Merck, Boehringer Ingelheim, AstraZeneca, Takeda Pharmaceutical, Novartis, Jiangsu Hansoh Pharmaceutical, Qilu Pharmaceutical, Beijing Tide Pharmaceutical and CTTQ, etc. The global five biggest players hold a share of % in 2024.
Global Dipeptidyl Peptidase-4 Inhibitors Scope and Market Size
Dipeptidyl Peptidase-4 Inhibitors market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Dipeptidyl Peptidase-4 Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the Dipeptidyl Peptidase-4 Inhibitors market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.
By Company
Merck
Boehringer Ingelheim
AstraZeneca
Takeda Pharmaceutical
Novartis
Jiangsu Hansoh Pharmaceutical
Qilu Pharmaceutical
Beijing Tide Pharmaceutical
CTTQ
Jiangsu Deyuan Pharmaceutical
Jiujiang Zhongtian Pharmaceutical
Yabao Pharmaceutical
Segment by Type
Sitagliptin
Saxagliptin
Vildagliptin
Linagliptin
Alogliptin
Other
Segment by Application
Hospital
Clinic
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Dipeptidyl Peptidase-4 Inhibitors definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Dipeptidyl Peptidase-4 Inhibitors companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Dipeptidyl Peptidase-4 Inhibitors in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Dipeptidyl Peptidase-4 Inhibitors sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices